Radiobiological and treatment planning study of a simultaneously integrated boost for canine nasal tumors using helical tomotherapy

Alonso N. Gutiérrez, Michael Deveau, Lisa J. Forrest, Wolfgang A. Tome, Thomas R. MacKie

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Feasibility of delivering a simultaneously integrated boost to canine nasal tumors using helical tomotherapy to improve tumor control probability (TCP) via an increase in total biological equivalent uniform dose (EUD) was evaluated. Eight dogs with varying size nasal tumors (5.8-110.9 cc) were replanned to 42 Gy to the nasal cavity and integrated dose boosts to gross disease of 45.2, 48.3, and 51.3 Gy in 10 fractions. EUD values were calculated for tumors and mean normalized total doses (NTD mean) for organs at risk (OAR). Normal Tissue Complication Probability (NTCP) values were obtained for OARs, and estimated TCP values were computed using a logistic dose-response model and based on deliverable EUD boost doses. Significant increases in estimated TCP to 54%, 74%, and 86% can be achieved with 10%, 23%, and 37% mean relative EUD boosts to the gross disease, respectively. NTCP values for blindness of either eye and for brain necrosis were <0.01% for all boosts. Values for cataract development were 31%, 42%, and 46% for studied boost schemas, respectively. Average NTD mean to eyes and brain for mean EUD boosts were 10.2, 11.3, and 12.1 Gy 3, and 7.5, 7.2, and 7.9 Gy 2, respectively. Using helical tomotherapy, simultaneously integrated dose boosts can be delivered to increase the estimated TCP at 1-year without significantly increasing the NTD mean to eyes and brain. Delivery of these treatments in a prospective trial may allow quantification of a dose-response relationship in canine nasal tumors.

Original languageEnglish (US)
Pages (from-to)594-602
Number of pages9
JournalVeterinary Radiology and Ultrasound
Volume48
Issue number6
DOIs
StatePublished - Nov 2007
Externally publishedYes

Fingerprint

Intensity-Modulated Radiotherapy
Nose
Canidae
planning
neoplasms
dogs
dosage
Neoplasms
Therapeutics
eyes
brain
Brain
dose response
Organs at Risk
Nasal Cavity
Blindness
nasal cavity
cataract
blindness
Cataract

Keywords

  • Boost dose
  • Canine nasal tumors
  • Intensity-modulated radiation therapy
  • Tomotherapy

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Radiobiological and treatment planning study of a simultaneously integrated boost for canine nasal tumors using helical tomotherapy. / Gutiérrez, Alonso N.; Deveau, Michael; Forrest, Lisa J.; Tome, Wolfgang A.; MacKie, Thomas R.

In: Veterinary Radiology and Ultrasound, Vol. 48, No. 6, 11.2007, p. 594-602.

Research output: Contribution to journalArticle

Gutiérrez, Alonso N. ; Deveau, Michael ; Forrest, Lisa J. ; Tome, Wolfgang A. ; MacKie, Thomas R. / Radiobiological and treatment planning study of a simultaneously integrated boost for canine nasal tumors using helical tomotherapy. In: Veterinary Radiology and Ultrasound. 2007 ; Vol. 48, No. 6. pp. 594-602.
@article{b2e6c6fc9816453b91ac3476b0232d8c,
title = "Radiobiological and treatment planning study of a simultaneously integrated boost for canine nasal tumors using helical tomotherapy",
abstract = "Feasibility of delivering a simultaneously integrated boost to canine nasal tumors using helical tomotherapy to improve tumor control probability (TCP) via an increase in total biological equivalent uniform dose (EUD) was evaluated. Eight dogs with varying size nasal tumors (5.8-110.9 cc) were replanned to 42 Gy to the nasal cavity and integrated dose boosts to gross disease of 45.2, 48.3, and 51.3 Gy in 10 fractions. EUD values were calculated for tumors and mean normalized total doses (NTD mean) for organs at risk (OAR). Normal Tissue Complication Probability (NTCP) values were obtained for OARs, and estimated TCP values were computed using a logistic dose-response model and based on deliverable EUD boost doses. Significant increases in estimated TCP to 54{\%}, 74{\%}, and 86{\%} can be achieved with 10{\%}, 23{\%}, and 37{\%} mean relative EUD boosts to the gross disease, respectively. NTCP values for blindness of either eye and for brain necrosis were <0.01{\%} for all boosts. Values for cataract development were 31{\%}, 42{\%}, and 46{\%} for studied boost schemas, respectively. Average NTD mean to eyes and brain for mean EUD boosts were 10.2, 11.3, and 12.1 Gy 3, and 7.5, 7.2, and 7.9 Gy 2, respectively. Using helical tomotherapy, simultaneously integrated dose boosts can be delivered to increase the estimated TCP at 1-year without significantly increasing the NTD mean to eyes and brain. Delivery of these treatments in a prospective trial may allow quantification of a dose-response relationship in canine nasal tumors.",
keywords = "Boost dose, Canine nasal tumors, Intensity-modulated radiation therapy, Tomotherapy",
author = "Guti{\'e}rrez, {Alonso N.} and Michael Deveau and Forrest, {Lisa J.} and Tome, {Wolfgang A.} and MacKie, {Thomas R.}",
year = "2007",
month = "11",
doi = "10.1111/j.1740-8261.2007.00304.x",
language = "English (US)",
volume = "48",
pages = "594--602",
journal = "Veterinary Radiology and Ultrasound",
issn = "1058-8183",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Radiobiological and treatment planning study of a simultaneously integrated boost for canine nasal tumors using helical tomotherapy

AU - Gutiérrez, Alonso N.

AU - Deveau, Michael

AU - Forrest, Lisa J.

AU - Tome, Wolfgang A.

AU - MacKie, Thomas R.

PY - 2007/11

Y1 - 2007/11

N2 - Feasibility of delivering a simultaneously integrated boost to canine nasal tumors using helical tomotherapy to improve tumor control probability (TCP) via an increase in total biological equivalent uniform dose (EUD) was evaluated. Eight dogs with varying size nasal tumors (5.8-110.9 cc) were replanned to 42 Gy to the nasal cavity and integrated dose boosts to gross disease of 45.2, 48.3, and 51.3 Gy in 10 fractions. EUD values were calculated for tumors and mean normalized total doses (NTD mean) for organs at risk (OAR). Normal Tissue Complication Probability (NTCP) values were obtained for OARs, and estimated TCP values were computed using a logistic dose-response model and based on deliverable EUD boost doses. Significant increases in estimated TCP to 54%, 74%, and 86% can be achieved with 10%, 23%, and 37% mean relative EUD boosts to the gross disease, respectively. NTCP values for blindness of either eye and for brain necrosis were <0.01% for all boosts. Values for cataract development were 31%, 42%, and 46% for studied boost schemas, respectively. Average NTD mean to eyes and brain for mean EUD boosts were 10.2, 11.3, and 12.1 Gy 3, and 7.5, 7.2, and 7.9 Gy 2, respectively. Using helical tomotherapy, simultaneously integrated dose boosts can be delivered to increase the estimated TCP at 1-year without significantly increasing the NTD mean to eyes and brain. Delivery of these treatments in a prospective trial may allow quantification of a dose-response relationship in canine nasal tumors.

AB - Feasibility of delivering a simultaneously integrated boost to canine nasal tumors using helical tomotherapy to improve tumor control probability (TCP) via an increase in total biological equivalent uniform dose (EUD) was evaluated. Eight dogs with varying size nasal tumors (5.8-110.9 cc) were replanned to 42 Gy to the nasal cavity and integrated dose boosts to gross disease of 45.2, 48.3, and 51.3 Gy in 10 fractions. EUD values were calculated for tumors and mean normalized total doses (NTD mean) for organs at risk (OAR). Normal Tissue Complication Probability (NTCP) values were obtained for OARs, and estimated TCP values were computed using a logistic dose-response model and based on deliverable EUD boost doses. Significant increases in estimated TCP to 54%, 74%, and 86% can be achieved with 10%, 23%, and 37% mean relative EUD boosts to the gross disease, respectively. NTCP values for blindness of either eye and for brain necrosis were <0.01% for all boosts. Values for cataract development were 31%, 42%, and 46% for studied boost schemas, respectively. Average NTD mean to eyes and brain for mean EUD boosts were 10.2, 11.3, and 12.1 Gy 3, and 7.5, 7.2, and 7.9 Gy 2, respectively. Using helical tomotherapy, simultaneously integrated dose boosts can be delivered to increase the estimated TCP at 1-year without significantly increasing the NTD mean to eyes and brain. Delivery of these treatments in a prospective trial may allow quantification of a dose-response relationship in canine nasal tumors.

KW - Boost dose

KW - Canine nasal tumors

KW - Intensity-modulated radiation therapy

KW - Tomotherapy

UR - http://www.scopus.com/inward/record.url?scp=35448963884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35448963884&partnerID=8YFLogxK

U2 - 10.1111/j.1740-8261.2007.00304.x

DO - 10.1111/j.1740-8261.2007.00304.x

M3 - Article

VL - 48

SP - 594

EP - 602

JO - Veterinary Radiology and Ultrasound

JF - Veterinary Radiology and Ultrasound

SN - 1058-8183

IS - 6

ER -